{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Iterum Therapeutics plc"},"Symbol":{"label":"Symbol","value":"ITRM"},"Address":{"label":"Address","value":"FITZWILLIAM COURT, 1ST FLOOR,LEESON CLOSE, DUBLIN, 2, Ireland"},"Phone":{"label":"Phone","value":"+353 16694820"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"Iterum Therapeutics PLC is a pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents."},"CompanyUrl":{"label":"Company Url","value":"https://www.iterumtx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Corey N. Fishman","title":"President, Chief Executive Officer & Director"},{"name":"Steven Aronin","title":"Senior Vice President & Head-Clinical Development"},{"name":"Tom Loughman","title":"Senior Vice President-Technical Operations"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}